Genmab A/S (GMAB) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
GMAB Revenue Analysis (2013–2024)
As of March 1, 2026, Genmab A/S (GMAB) generated trailing twelve-month (TTM) revenue of $14.04 billion, reflecting significant decline in growth of -81.6% year-over-year. The most recent quarter (Q3 2025) recorded $1.02 billion in revenue, down 82.6% sequentially.
Looking at the longer-term picture, GMAB's 5-year compound annual growth rate (CAGR) stands at +32.0%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $21.53 billion in 2024, representing a new all-time high.
When compared to Healthcare sector peers including INCY (+21.2% YoY), EXEL (+9.9% YoY), and IBRX (+1026.0% YoY), GMAB has underperformed the peer group in terms of revenue growth. Compare GMAB vs INCY →
Peer Comparison
Compare GMAB's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GMABCurrent | $14.0B | -81.6% | +32.0% | 31.1% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% | |
| CGON | $1M | +217.8% | - | -10067.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $21.53B | +30.7% | $20.54B | 95.4% | $6.70B | 31.1% |
| 2023 | $16.47B | +13.6% | $16.25B | 98.6% | $5.32B | 32.3% |
| 2022 | $14.51B | +72.3% | $14.51B | 100.0% | $6.27B | 43.2% |
| 2021 | $8.42B | -16.8% | $8.42B | 100.0% | $2.95B | 35.1% |
| 2020 | $10.11B | +88.4% | $10.11B | 100.0% | $6.31B | 62.4% |
| 2019 | $5.37B | +77.4% | $5.37B | 100.0% | $2.64B | 49.2% |
| 2018 | $3.03B | +27.9% | $3.03B | 100.0% | $1.38B | 45.6% |
| 2017 | $2.37B | +30.2% | $2.37B | 100.0% | $1.34B | 56.8% |
| 2016 | $1.82B | +60.3% | $1.82B | 100.0% | $1.05B | 58.0% |
| 2015 | $1.13B | +33.2% | $1.13B | 100.0% | $730.4M | 64.5% |
See GMAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GMAB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GMAB vs AGIO
See how GMAB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GMAB's revenue growth accelerating or slowing?
GMAB revenue declined -81.6% year-over-year, contrasting with the 5-year CAGR of +32.0%. TTM revenue fell to $14.0B. This reverses the prior growth trend.
What is GMAB's long-term revenue growth rate?
Genmab A/S's 5-year revenue CAGR of +32.0% reflects the variable expansion pattern. Current YoY growth of -81.6% is below this long-term average.
How is GMAB's revenue distributed by segment?
GMAB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.